
NICE does not recommend pembrolizumab (Keytruda) to treat platinum-resistant recurrent ovarian cancer on the NHS in England, Wales and Northern Ireland. Over 3000 people have signed our open letter to challenge this decision. Add your name today 👉 targetovariancancer.eaction.…
















